These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30730661)

  • 1. Drug-induced posterior reversible encephalopathy syndrome.
    Prescrire Int; 2017 Apr; 26(181):98-101. PubMed ID: 30730661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment.
    Laruelle M; Filleul B; Duprez T; Machiels JP
    Urol Int; 2018; 100(3):357-360. PubMed ID: 26845702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
    Tlemsani C; Mir O; Boudou-Rouquette P; Huillard O; Maley K; Ropert S; Coriat R; Goldwasser F
    Target Oncol; 2011 Dec; 6(4):253-8. PubMed ID: 22090260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
    Abbas O; Shamseddin A; Temraz S; Haydar A
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23436889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib induced unilateral posterior reversible encephalopathy syndrome.
    Arslan BM; Bajrami A; Demir E; Cabalar M; Yayla V
    Ideggyogy Sz; 2017 Mar; 70(3-4):140-144. PubMed ID: 29870619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Dec; 22(6):806-810. PubMed ID: 26467267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy.
    Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):301-3. PubMed ID: 20565319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
    Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
    J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
    Shah RR
    Drug Saf; 2017 May; 40(5):373-386. PubMed ID: 28181126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
    Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
    Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.
    Tlemsani C; Mir O; Psimaras D; Vano YA; Ducreux M; Escudier B; Rousseau B; Loirat D; Ceccaldi B; André T; Goldwasser F; Ricard D
    Eur J Cancer; 2016 Oct; 66():75-82. PubMed ID: 27529757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posterior reversible encephalopathy syndrome: a case study.
    Wright KL; Polito MH; French AE
    Am J Nurs; 2012 May; 112(5):36-40; quiz 41-2. PubMed ID: 22546734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.
    Kim CA; Price-Hiller J; Chu QS; Tankel K; Hennig R; Sawyer MB; Spratlin JL
    Invest New Drugs; 2014 Oct; 32(5):1036-45. PubMed ID: 24853074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide-induced posterior reversible encephalopathy syndrome (PRES): a case report.
    Jayaweera JL; Withana MR; Dalpatadu CK; Beligaswatta CD; Rajapakse T; Jayasinghe S; Chang T
    J Med Case Rep; 2014 Dec; 8():442. PubMed ID: 25519913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
    Tavil B; Isgandarova F; Bayhan T; Unal S; Kuskonmaz B; Gumruk F; Cetin M
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):240-2. PubMed ID: 26907662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.
    Seet RC; Rabinstein AA
    QJM; 2012 Jan; 105(1):69-75. PubMed ID: 21865314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posterior reversible encephalopathy syndrome following a scorpion sting.
    Porcello Marrone LC; Marrone BF; Neto FK; Costa FC; Thomé GG; Aramburu MB; Schilling LP; Pascoal TA; Gadonski G; Huf Marrone AC; da Costa JC
    J Neuroimaging; 2013 Oct; 23(4):535-6. PubMed ID: 23551823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 19. Focal segmental glomerulosclerosis in children complicated by posterior reversible encephalopathy syndrome.
    Stârcea M; Gavrilovici C; Munteanu M; Miron I
    J Int Med Res; 2018 Mar; 46(3):1172-1177. PubMed ID: 29310486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU.
    Massey J
    J Clin Neurosci; 2017 Jun; 40():57-59. PubMed ID: 28238523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.